rESEARCH AND DEVELOPMENT
High quality, targeted formulations with minimal inactive excipients
Open‑label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/ chronic fatigue syndrome: neuropsychological symptoms and sex comparisons
Authors: Amy Wallis* , Michelle Ball, Henry Butt, Donald P. Lewis, Sandra McKechnie4, Phillip Paull, Amber Jaa‑Kwee4 and Dorothy Bruck
As of 2014 Spectrumceuticals® has been actively sponsoring and participating in human clinical trials within Australia whilst developing unique ingredients for future therapeutic preparations
We are focused on delivering high quality, targeted formulations with minimal inactive excipients, manufactured in selected TGA-licensed production facilities within Australia.
Our formulations have been approved and listed with supporting clinical studies and scientific reviews by the high standards of the Therapeutic Goods Administration.
Research and development of our products is conducted by our Director of Research and Education in conjunction with our regulatory advisers, manufacturing partners and ingredient laboratories.
The relevance and applicability of scholarly and clinical studies to individuals with food allergies, intolerances and specific dietary requirements
The quality and comprehensiveness of the clinical reviews of the active ingredients
The safety of the researched formulation needed to achieve efficacy
Our ability to achieve a stable formulation with minimal inactive ingredients